<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autoradiography was utilized to explore the patterns of distribution of two different monoclonal antibodies (Lym-1 and TNT-1) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="1" pm="."><plain>Lym-1 is an antibody against a cell surface B-cell antigen </plain></SENT>
<SENT sid="2" pm="."><plain>In comparison, TNT-1 represents a novel approach and is an antibody against an intracellular (nuclear) antigen that is selectively revealed in degenerating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Experimentally <z:chebi fb="60" ids="24859">iodine</z:chebi>-125-(125I) labeled Lym-1 or TNT-1 was injected intravenously into <z:mp ids='MP_0003815'>nude</z:mp> mice bearing either the Raji <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or the ME-180 human cervical <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Qualitative autoradiographic analyses performed after injection revealed that Lym-1 accumulated at the periphery of the target <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> where vascular permeability is marked and where Lym-1 positive cells are first encountered </plain></SENT>
<SENT sid="5" pm="."><plain>By contrast, TNT-1 lost its initial peripheral distribution and demonstrated progressive concentration in the center of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> where binding to its nuclear antigen is facilitated by the presence of cell degeneration and <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>These studies confirm the ability of TNT-1 to bind areas deep within <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> that traditionally are considered inaccessible to antibodies administered for imaging and therapy </plain></SENT>
</text></document>